Only 50% of patients with relapsed Hodgkin lymphoma (HL) can be cured with intensive induction chemotherapy, followed by high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT). Based on the results of the HDR2 trial two courses of DHAP and subsequent HDCT/ASCT are the current standard of care in relapsed HL. In order to assess the prognostic relevance of DHAP dose density, we performed a retrospective multivariate analysis of the HDR2 trial (N=266). In addition to four risk factors (early or multiple relapse, stage IV disease or anemia at relapse, and grade IV hematotoxicity during the first cycle of DHAP) a delayed start of the second cycle of DHAP>day 22 predicted a significantly poorer progression-free survival (PFS, p=0.0356) and overall survival (OS, p=0.0025). In conclusion, our analysis strongly suggests that dose density of DHAP has a relevant impact on the outcome of relapsed HL patients.

b University Hospital Brno and Faculty of Medicine Masaryk University Brno Czech Republic ;

c Department of Hematology and Oncology Hospital of Oldenburg Oldenburg Germany ;

Clinic 3 for Internal Medicine University Hospital of Ulm Ulm Germany ;

e Department of Hematology and Oncology University Hospital of Magdeburg Magdeburg Germany ;

f Department of Hematology and Oncology University Hospital of Leipzig Leipzig Germany ;

g Department of Hematology Oncology Asklepios Clinic St Georg Hamburg Germany ;

h Department of Oncology Hematology Klinikum Nuernberg Nord Nuernberg Germany ;

i Department of Hematology Radboud University Medical Center Nijmegen Netherlands ;

Internal Medicine 1 German Hodgkin Study Group University Hospital of Cologne Cologne Germany ;

j Clinic 1 for Internal Medicine Helios Clinic Wuppertal Wuppertal Germany

Citace poskytuje Crossref.org

Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial